ClinicalTrials.gg
CompletedNCT00486278Updated Mar 7, 2017Results posted

Haemophilia Patients With Inhibitors Being Treated for Acute Joint Bleeds

A Phase 2 interventional study of eptacog alfa (activated) and vatreptacog alfa (activated) in Congenital Bleeding Disorder, Haemophilia A and Haemophilia B, sponsored by Novo Nordisk A/S. Completed at 45 sites in 18 countries. Open to male participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2017-03-07.

Sponsored by Novo Nordisk A/S · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
51
Allocation
Randomized
Ages
12 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing recombinant FVIIa in Hemophilia A — 1 open to participants now, 1 under way, none of them phase 3. recombinant FVIIa · Hemophilia A.

Enrollment
4th of 19
51 · median 24
Started
2007
the only one that year
Phase 2
3 of 20
none open now
Registered
5th of 20
by date
Lead sponsor
11 of 20
Novo Nordisk A/S

Among the 20 studies testing recombinant FVIIa in Hemophilia A, this one is the 4th largest by enrollment of the 19 interventional ones that give a count, is the only one that started in 2007, is one of 3 in phase 2, and was the 5th registered.

Hemophilia A

844 studies on the registry are indexed under Hemophilia A; 136 are open to participants now.

Browse Hemophilia A studies →

Open to participants now

1 of the 20 studies testing recombinant FVIIa in Hemophilia A is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About recombinant FVIIa

recombinant FVIIa: first FDA approval 1999 (Novoseven, Novoseven Rt), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 87 Hemophilia A studies recruiting now, 51 (59%) set no upper age limit and 31 (36%) stop at 75 or younger; 55 take children under 18; 10 take healthy volunteers.

This study: 12 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing recombinant FVIIa in Hemophilia A, or all of them as a file.
02

Study summary

This trial is conducted in Africa, Asia, Europe, Japan, and North and South America.

The aim of this trial is to evaluate the safety and efficacy of activated recombinant human factor VII analogue (vatreptocog alfa (activated)) in haemophilia patients with inhibitors.

03

Conditions studied

  • Congenital Bleeding Disorder
  • Haemophilia A
  • Haemophilia B
04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 12 years of age or older (at least 18 years in Croatia, France and United Kingdom (UK))
  • Clinical diagnosis of congenital haemophilia A or B with a current positive inhibitor titre and a known peak inhibitor of above 5 Bethesda units (BU) (present or in the past) to human FVIII or IX and known antihuman FVIII or IX anamnestic response
  • Minimum of 2 joint bleeds (haemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 6 months, or at least 4 joint bleeds (hemarthroses of ankles, knees, or elbows) requiring haemostatic drug treatment within the previous 12 months at trial entry

Exclusion criteria

Exclusion Criteria:

  • Known allergy to rFVIIa, and/or suspected allergy to trial product
  • count lower than 50,000 mm\^3 based on medical records at trial entry (visit 1)
  • Any clinical signs or history of thromboembolic events
  • Advanced atherosclerotic disease
  • Severe liver disease based on medical records within the past 12 months at trial entry (Visit 1), as defined by (ALAT) above 3 times the reference range
  • Known active pseudo tumours (documented bleeding requiring treatment within the last 3 months
  • Subject had any (major) surgical procedure in the 30 days prior to screening into the trial. a. Catheter, ports and dental extractions do not count as surgeries and will not exclude the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    vatreptacog alfa 5 mcg/kg

    Drug: vatreptacog alfa (activated)

  • Experimental
    vatreptacog alfa 10 mcg/kg

    Drug: vatreptacog alfa (activated)

  • Experimental
    vatreptacog alfa 20 mcg/kg

    Drug: vatreptacog alfa (activated)

  • Experimental
    vatreptacog alfa 40 mcg/kg

    Drug: vatreptacog alfa (activated)

  • Experimental
    vatreptacog alfa 80 mcg/kg

    Drug: vatreptacog alfa (activated)

  • Experimental
    rFVIIa 90 mcg/kg

    Drug: eptacog alfa (activated)

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Adverse Events (AEs)

    Adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

    Time frame: Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.

Secondary outcomes

  1. Activated Recombinant Human Factor VII Analogue Activity in the Blood

    Time frame: 0-24 hours after trial product administration

  2. Prothrombin Time (PT)

    The test measures the clotting time of plasma following the activation of tissue factor (TF also called thromboplastin) and calcium to hypocalcemic plasma. PT was provided in percent based on the measured PT in seconds and related/converted with the relevant standard curve. The percent value was derived based on the hyperbolic relation between PT (sec) and % PT activity.

    Time frame: pre-dose - 12 hours after trial product administration

  3. F1 + 2 (Prothrombin Fragments 1+2)

    Thrombin and F1+2 are formed in equimolar quantities by the enzymatic cleavage of prothrombin (FII), and F1+2 thus indicate that thrombin has been generated.

    Time frame: pre-dose - 12 hours after trial product administration

  4. Activated Partial Thromboplastin Time (aPTT)

    The aPTT time measured in clinical samples reflects both the effect of the drugs (generation of thrombin and FXa) and the presence of rFVIIa /rFVIIa analogue in the plasma samples causing a dose dependent shortening of the clotting time.

    Time frame: pre-dose - 12 hours after trial product administration

  5. Cessation of Bleeding: Number of Doses Needed to Control Bleeding

    Time frame: Within 9 hours after first trial product administration or need of additional haemostatic medication within 9 hours after first trial administration additional haemostatic agents required to control bleed (treatment failure)

  6. Number of Subjects With Need for Additional Haemostatic Agents

    Time frame: within 24 hours after successful control of bleeding episode with trial product

  7. Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )

    Time frame: 0-24 hours after trial product administration

  8. Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)

    Time frame: 0-24 hours after trial product administration

  9. Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)

    Time frame: 0-24 hours after trial product administration

  10. Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)

    Time frame: 0-24 hours after trial product administration

  11. Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)

    Time frame: 0-24 hours after trial product administration

  12. Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)

    Time frame: 0-24 hours after trial product administration

  13. Immunogenicity (Inhibitor Development)

    Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or rFVIIa.

    Time frame: Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.

  14. Biochemistry: ALAT (Alanine Aminotransferase)

    Time frame: screening visit, pre-dose and 12 hours after dosing

  15. Biochemistry: Creatinine

    Time frame: screening visit, pre-dose and 12 hours after dosing

  16. Haematology: Haemoglobin

    Time frame: screening visit, pre-dose and 12 hours after dosing

  17. Haematology: Red Cell Count

    Time frame: screening visit, pre-dose and 12 hours after dosing

  18. Haematology: Packed Cell Volume

    Time frame: screening visit, pre-dose and 12 hours after dosing

  19. Haematology: White Cell Count

    Time frame: screening visit, pre-dose and 12 hours after dosing

  20. Haematology: Platelet Count

    Time frame: screening visit, pre-dose and 12 hours after dosing

07

Results

Posted Dec 25, 2014

Participant flow

A total of 40 sites were initiated globally in 18 countries, including Argentina, Brazil, Canada, Croatia, France, Hungary, Israel, Italy, Japan, Malaysia, Poland, South Africa, Spain, Turkey, Taiwan, Thailand, the United Kingdom and the United States

Participant flow — Overall Study
MilestoneAll Subjects
Started51
Completed42
Not completed9
Withdrew: Adverse event5
Withdrew: Withdrawal by subject2
Withdrew: Physician decision2

Outcome measures

PrimaryNumber of Adverse Events (AEs)

Adverse event is defined as any untoward medical occurrence in a patient or clinical investigation patient administered a pharmaceutical product and which does not necessarily have to have a causal relationship with this treatment.

Time frame:
Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.
Reported as:
Number · events
Number of Adverse Events (AEs)
eventsVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
All AEs10855011
Serious AEs352203
SecondaryActivated Recombinant Human Factor VII Analogue Activity in the Blood
Time frame:
0-24 hours after trial product administration
Reported as:
Mean · IU/mL
Activated Recombinant Human Factor VII Analogue Activity in the Blood
IU/mLVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pre-dose——0.1 ± 0.10.1 ± 00 ± 00.1 ± 0
1 hours post-dose——5.3 ± 1.312.8 ± 5.319.7 ± 7.228.0 ± 12.6
12 hours post-dose——0.4 ± 0.42.3 ± 4.50.3 ± 0.314.1 ± 27.3
24 hours post-dose——0 ± 00 ± 00 ± 00.1 ± 0
SecondaryProthrombin Time (PT)

The test measures the clotting time of plasma following the activation of tissue factor (TF also called thromboplastin) and calcium to hypocalcemic plasma. PT was provided in percent based on the measured PT in seconds and related/converted with the relevant standard curve. The percent value was derived based on the hyperbolic relation between PT (sec) and % PT activity.

Time frame:
pre-dose - 12 hours after trial product administration
Reported as:
Mean · percentage (%)
Prothrombin Time (PT)
percentage (%)Vatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pre-dose80.1 ± 12.677.6 ± 19.179.1 ± 14.985.9 ± 15.585.5 ± 8.888.3 ± 25.6
1 hours post-dose84.3 ± 16.399.6 ± 17.9112.1 ± 14.6123.4 ± 14.7128.5 ± 7.6139.0 ± 0
12 hours post-dose82.1 ± 16.273.2 ± 19.286.9 ± 14.194.5 ± 17.592.3 ± 16.8112.1 ± 29.1
SecondaryF1 + 2 (Prothrombin Fragments 1+2)

Thrombin and F1+2 are formed in equimolar quantities by the enzymatic cleavage of prothrombin (FII), and F1+2 thus indicate that thrombin has been generated.

Time frame:
pre-dose - 12 hours after trial product administration
Reported as:
Mean · pmol/L
F1 + 2 (Prothrombin Fragments 1+2)
pmol/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pre-dose289.8 ± 310.9131.8 ± 48.7139.1 ± 50.4121.2 ± 34.5125.4 ± 45.9169.3 ± 56.9
1 hour post-dose443.7 ± 414.7241.7 ± 162.0401.6 ± 292.6365.9 ± 145.4385.7 ± 88.8309.7 ± 284.5
12 hour post-dose325.9 ± 299.4198.9 ± 250.9158.6 ± 54.5199.8 ± 91.5136.9 ± 43.8268.2 ± 158.0
SecondaryActivated Partial Thromboplastin Time (aPTT)

The aPTT time measured in clinical samples reflects both the effect of the drugs (generation of thrombin and FXa) and the presence of rFVIIa /rFVIIa analogue in the plasma samples causing a dose dependent shortening of the clotting time.

Time frame:
pre-dose - 12 hours after trial product administration
Reported as:
Mean · Sec
Activated Partial Thromboplastin Time (aPTT)
SecVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pre-dose120.6 ± 22.6126.0 ± 26.4122.8 ± 15.9119.2 ± 31.3117.4 ± 17.9113.8 ± 17.4
1 hours post-dose102.1 ± 19.479.7 ± 13.968.7 ± 15.752.8 ± 14.148.6 ± 24.070.0 ± 9.8
12 hours post-dose111.7 ± 22.4107.9 ± 27.7107.9 ± 14.8104.4 ± 31.299.3 ± 19.698.6 ± 20.8
SecondaryCessation of Bleeding: Number of Doses Needed to Control Bleeding
Time frame:
Within 9 hours after first trial product administration or need of additional haemostatic medication within 9 hours after first trial administration additional haemostatic agents required to control bleed (treatment failure)
Reported as:
Number · bleeding episodes
Cessation of Bleeding: Number of Doses Needed to Control Bleeding
bleeding episodesVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
1 dose332546
2 doses597644
3 doses447427
treatment failure330102
SecondaryNumber of Subjects With Need for Additional Haemostatic Agents
Time frame:
within 24 hours after successful control of bleeding episode with trial product
Reported as:
Number · participants
Number of Subjects With Need for Additional Haemostatic Agents
participantsVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Number of Subjects With Need for Additional Haemostatic Agents411111
SecondaryPharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )
Time frame:
0-24 hours after trial product administration
Reported as:
Geometric mean · (IU*h)/mL
Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )
(IU*h)/mLVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmacokinetic Parameters Based on FVIIa Activity: AUC 0-t (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to the Time (t) )——34.24 ± 27.0066.85 ± 50.51136.19 ± 18.5674.35 ± 45.30
SecondaryPharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)
Time frame:
0-24 hours after trial product administration
Reported as:
Geometric mean · (IU*h)/mL
Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)
(IU*h)/mLVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmacokinetic Parameters Based on FVIIa Activity: AUC(0-inf) (Area Under the Plasma FVIIa Activity-time Curve From Time Zero to Infinity)——35.76 ± 26.3471.23 ± 55.42139.63 ± 18.35101.38 ± 40.77
SecondaryPharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)
Time frame:
0-24 hours after trial product administration
Reported as:
Mean · hours
Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)
hoursVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmacokinetic Parameters Based on FVIIa Activity: MRT (Mean Residence Time)——0.68 ± 0.160.88 ± 0.330.56 ± 0.102.23 ± 0.54
SecondaryPharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)
Time frame:
0-24 hours after trial product administration
Reported as:
Mean · hours
Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)
hoursVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmacokinetic Parameters Based on FVIIa Activity: t½ (Terminal Half-life)——0.92 ± 0.181.28 ± 1.280.71 ± 0.161.66 ± 0.35
SecondaryPharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)
Time frame:
0-24 hours after trial product administration
Reported as:
Median · mL/h
Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)
mL/hVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmacokinetic Parameters Based on FVIIa Activity: CL (Total Clearance)——9365.8 (6829.8 to 15065)11247 (5315.6 to 21314)10409 (6262.9 to 13276)3078.3 (1636.9 to 5039.4)
SecondaryPharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)
Time frame:
0-24 hours after trial product administration
Reported as:
Median · mL/kg
Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)
mL/kgVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Pharmakokinetic Parameters Based on FVIIa Activity: Vss (Distribution Volume at Steady State)——5396.9 (3319.1 to 12215)9597.0 (5522.7 to 18310)5538.7 (4210.7 to 6482.6)6696.7 (3037.3 to 10328)
SecondaryImmunogenicity (Inhibitor Development)

Immunogenicity was tested by formation of neutralising antibodies towards vatreptacog alfa and/or rFVIIa.

Time frame:
Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.
Reported as:
Number · participants
Immunogenicity (Inhibitor Development)
participantsVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Immunogenicity (Inhibitor Development)000000
SecondaryBiochemistry: ALAT (Alanine Aminotransferase)
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · U/L
Biochemistry: ALAT (Alanine Aminotransferase)
U/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening26.0 ± 18.732.8 ± 31.330.6 ± 27.139.3 ± 33.324.2 ± 17.930.1 ± 21.4
Pre-dose22.7 ± 19.929.9 ± 23.032.4 ± 37.129.1 ± 16.428.1 ± 16.649.4 ± 73.7
12 hours post-dose20.1 ± 16.825.6 ± 19.221.4 ± 15.430.9 ± 18.224.5 ± 14.445.1 ± 66.0
SecondaryBiochemistry: Creatinine
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · micromol/L
Biochemistry: Creatinine
micromol/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening66.9 ± 23.667.2 ± 13.863.6 ± 23.367.7 ± 15.760.0 ± 17.366.9 ± 16.0
Pre-dose68.2 ± 23.370.1 ± 10.069.8 ± 15.369.1 ± 19.167.7 ± 10.871.1 ± 15.2
12 hours post-dose58.3 ± 23.663.1 ± 17.770.6 ± 16.871.9 ± 15.268.0 ± 10.770.6 ± 14.8
SecondaryHaematology: Haemoglobin
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · g/dL
Haematology: Haemoglobin
g/dLVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening13.9 ± 1.814.7 ± 1.614.2 ± 1.414.2 ± 1.814.6 ± 1.313.8 ± 1.3
Pre-dose13.8 ± 2.314.6 ± 1.714.4 ± 1.213.9 ± 2.114.8 ± 1.314.1 ± 1.3
12 hours post-dose13.5 ± 2.213.9 ± 1.713.7 ± 1.213.0 ± 2.214.2 ± 0.813.5 ± 1.3
SecondaryHaematology: Red Cell Count
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · 10^12 cells/L
Haematology: Red Cell Count
10^12 cells/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening5.0 ± 0.55.4 ± 0.95.3 ± 1.05.1 ± 0.45.7 ± 1.25.3 ± 1.0
Pre-dose5.1 ± 0.55.1 ± 0.45.2 ± 0.45.1 ± 0.45.1 ± 0.45.2 ± 0.5
12 hours post-dose5.0 ± 0.74.9 ± 0.44.9 ± 0.34.8 ± 0.54.9 ± 0.35.0 ± 0.6
SecondaryHaematology: Packed Cell Volume
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · percentage (%)
Haematology: Packed Cell Volume
percentage (%)Vatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening41.6 ± 5.143.7 ± 3.942.2 ± 3.642.4 ± 4.344.0 ± 3.341.6 ± 3.8
Pre-dose41.3 ± 6.143.1 ± 4.042.6 ± 3.242.5 ± 6.344.6 ± 4.642.3 ± 3.5
12 hours post-dose40.6 ± 6.040.9 ± 4.040.6 ± 2.939.9 ± 6.842.2 ± 2.940.4 ± 3.8
SecondaryHaematology: White Cell Count
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · 10^9 cells/L
Haematology: White Cell Count
10^9 cells/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening6.7 ± 1.96.3 ± 2.57.2 ± 2.46.9 ± 2.76.6 ± 1.55.8 ± 1.8
Pre-dose7.6 ± 2.37.3 ± 2.67.8 ± 1.97.1 ± 2.27.1 ± 2.36.5 ± 2.1
12 hours post-dose7.7 ± 3.47.2 ± 2.18.2 ± 2.07.3 ± 2.66.8 ± 1.47.1 ± 2.5
SecondaryHaematology: Platelet Count
Time frame:
screening visit, pre-dose and 12 hours after dosing
Reported as:
Mean · 10^9 cells/L
Haematology: Platelet Count
10^9 cells/LVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Screening259.8 ± 96.2253.8 ± 82.9250.8 ± 61.2276.1 ± 75.5272.5 ± 73.2259.0 ± 86.1
Pre-dose253.5 ± 90.5248.6 ± 65.2252.7 ± 50.8278.8 ± 78.0278.1 ± 59.0271.1 ± 82.4
12 hours post-dose242.7 ± 83.7244.8 ± 57.4255.8 ± 61.9287.0 ± 94.8266.8 ± 53.1260.7 ± 69.4

Adverse events

Collected over Monitoring of adverse events was performed from start of the trial to approximately 4 weeks after administration of trial product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Vatreptacog Alfa 5 mcg/kg—2/16 (12.5%)6/16 (37.5%)
Vatreptacog Alfa 10 mcg/kg—3/19 (15.8%)3/19 (15.8%)
Vatreptacog Alfa 20 mcg/kg—2/16 (12.5%)3/16 (18.8%)
Vatreptacog Alfa 40 mcg/kg—2/16 (12.5%)1/16 (6.3%)
Vatreptacog Alfa 80 mcg/kg—0/10 (0%)0/10 (0%)
rFVIIa 90 mcg/kg—2/19 (10.5%)8/19 (42.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Colonic polypGastrointestinal disorders0/160/190/161/160/100/19
Device dislocationGeneral disorders1/160/190/160/160/100/19
Facial bones fractureInjury, poisoning and procedural complications0/160/191/160/160/100/19
Femoral neck fractureInjury, poisoning and procedural complications0/160/190/161/160/100/19
Compartment syndromeMusculoskeletal and connective tissue disorders0/160/191/160/160/100/19
HaematuriaRenal and urinary disorders1/160/190/160/160/100/19
AneurysmVascular disorders1/160/190/160/160/100/19
DyspepsiaGastrointestinal disorders0/161/190/160/160/100/19
CholecystitisHepatobiliary disorders0/161/190/160/160/100/19
Arthritis bacterialInfections and infestations0/160/190/160/160/101/19
Most frequent other events
Showing 10 of 19
Most frequent other events
EventVatreptacog Alfa 5 mcg/kgVatreptacog Alfa 10 mcg/kgVatreptacog Alfa 20 mcg/kgVatreptacog Alfa 40 mcg/kgVatreptacog Alfa 80 mcg/kgrFVIIa 90 mcg/kg
Incorrect dose administeredInjury, poisoning and procedural complications3/160/190/160/160/100/19
DiarrhoeaGastrointestinal disorders0/162/190/160/160/100/19
NauseaGastrointestinal disorders0/160/190/161/160/100/19
Teeth brittleGastrointestinal disorders0/160/191/160/160/100/19
Infusion site extravasationGeneral disorders0/160/191/160/160/100/19
Injection site haematomaGeneral disorders1/160/190/160/160/100/19
Injection site haemorrhageGeneral disorders1/160/190/160/160/101/19
NasopharyngitisInfections and infestations1/161/190/160/160/100/19
DizzinessNervous system disorders0/160/190/161/160/100/19
HeadacheNervous system disorders1/160/190/160/160/100/19

Baseline characteristics

Age, Continuous
Age, Continuous(years)All Subjects
Mean28 ± 12.4
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female0
Male51
08

Study locations

45 sites
  • Novo Nordisk Investigational Site
    Los Angeles, California 90027, United States
  • Novo Nordisk Investigational Site
    Augusta, Georgia 30912, United States
  • Novo Nordisk Investigational Site
    Chicago, Illinois 60612-3833, United States
  • Novo Nordisk Investigational Site
    Indianapolis, Indiana 46260, United States
  • Novo Nordisk Investigational Site
    Iowa City, Iowa 52242, United States
  • Novo Nordisk Investigational Site
    Boston, Massachusetts 02115, United States
  • Novo Nordisk Investigational Site
    Ann Arbor, Michigan 48109-5235, United States
  • Novo Nordisk Investigational Site
    Minneapolis, Minnesota 55455, United States
  • Novo Nordisk Investigational Site
    New York, New York 10029, United States
  • Novo Nordisk Investigational Site
    Chapel Hill, North Carolina 27599-7035, United States
  • Novo Nordisk Investigational Site
    Cincinnati, Ohio 45229, United States
  • Novo Nordisk Investigational Site
    Portland, Oregon 97239-3011, United States
  • Novo Nordisk Investigational Site
    Ciudad Autónoma de Bs. As., C1425ASU, Argentina
  • Novo Nordisk Investigational Site
    Campinas, Sao Paulo 13081970, Brazil
  • Novo Nordisk Investigational Site
    Rio de Janeiro, 20211-030, Brazil
  • Novo Nordisk Investigational Site
    São Paulo, 04024-002, Brazil
  • Novo Nordisk Investigational Site
    Edmonton, Alberta T6G 2B7, Canada
  • Novo Nordisk Investigational Site
    Zagreb, 10 000, Croatia
  • Novo Nordisk Investigational Site
    Lyon, 69003, France
  • Novo Nordisk Investigational Site
    Budapest, H-1134, Hungary
  • Novo Nordisk Investigational Site
    Debrecen, 4012, Hungary
  • Novo Nordisk Investigational Site
    Tel-Hashomer, 52621, Israel
  • Novo Nordisk Investigational Site
    Castelfranco Veneto, 31033, Italy
  • Novo Nordisk Investigational Site
    Firenze, 50134, Italy
  • Novo Nordisk Investigational Site
    Milano, 20124, Italy
  • Novo Nordisk Investigational Site
    Hiroshima-shi, Hiroshima, 734 8551, Japan
  • Novo Nordisk Investigational Site
    Itabashi-ku, Tokyo, 173 8606, Japan
  • Novo Nordisk Investigational Site
    Kashihara-shi, Nara, 634 8522, Japan
  • Novo Nordisk Investigational Site
    Nagoya-shi, Aichi, 466 8560, Japan
  • Novo Nordisk Investigational Site
    Nishinomiya-shi, 663 8051, Japan
  • Novo Nordisk Investigational Site
    Kuala Lumpur, 50400, Malaysia
  • Novo Nordisk Investigational Site
    Warszawa, 02-776, Poland
  • Novo Nordisk Investigational Site
    Parktown Johannesburg, Gauteng 2193, South Africa
  • Novo Nordisk Investigational Site
    Durban, KwaZulu-Natal 4013, South Africa
  • Novo Nordisk Investigational Site
    Cape Town, 7925, South Africa
  • Novo Nordisk Investigational Site
    Madrid, 28046, Spain
  • Novo Nordisk Investigational Site
    Changhua, 500, Taiwan
  • Novo Nordisk Investigational Site
    Taipei, 100, Taiwan
  • Novo Nordisk Investigational Site
    Bangkok, 10400, Thailand
  • Novo Nordisk Investigational Site
    Adana, 01130, Turkey
  • Novo Nordisk Investigational Site
    Ankara, 06100, Turkey
  • Novo Nordisk Investigational Site
    Antalya, 01010, Turkey
  • Novo Nordisk Investigational Site
    Bornova-IZMIR, 35100, Turkey
  • Novo Nordisk Investigational Site
    London, SE1 7EH, United Kingdom
  • Novo Nordisk Investigational Site
    Manchester, M13 9WL, United Kingdom
09

References and documents

Publications

  • de Paula EV, Kavakli K, Mahlangu J, Ayob Y, Lentz SR, Morfini M, Nemes L, Salek SZ, Shima M, Windyga J, Ehrenforth S, Chuansumrit A; 1804 (adept(TM)1) Investigators. Recombinant factor VIIa analog (vatreptacog alfa [activated]) for treatment of joint bleeds in hemophilia patients with inhibitors: a randomized controlled trial. J Thromb Haemost. 2012 Jan;10(1):81-9. doi: 10.1111/j.1538-7836.2011.04549.x. PubMed 22470921 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2007, a primary completion of Jun 2010 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2014, 4 years 6 months after primary completion. A results delay was requested in Nov 2010.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 13, 2007
First posted
Jun 14, 2007
Start
Jun 2007
Primary completionActual
Jun 2010
CompletionActual
Jun 2010
Results delay requested
Nov 5, 2010
Results first posted
Dec 25, 2014
Last update
Mar 7, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 7, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00486278
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Jun 14, 2007
Start date
Jun 2007
Primary completion
Jun 2010
Completion
Jun 2010
Results posted
Dec 25, 2014
Last update
Mar 7, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Recombinant FVIIa · Vatreptacog alfa

Start the discussion